CMA issues charges in second pay-for-delay case
The UK’s competition authority has accused two pharmaceutical companies of entering anticompetitive agreements that boosted prices the country’s National Health Service paid for anti-inflammatory drug hydrocortisone
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.